Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

External validation of prediction models for mortality in an incident dialysis population
.

Mavrakanas TA, Asfour K, Vasilevsky M, Barré PE, Alam A.

Clin Nephrol. 2019 Feb;91(2):65-71. doi: 10.5414/CN109310.

PMID:
30526813
2.

Serial versus single troponin measurements for the prediction of cardiovascular events and mortality in stable chronic haemodialysis patients.

Mavrakanas TA, Sniderman AD, Barré PE, Alam A.

Nephrology (Carlton). 2018 Jan;23(1):69-74. doi: 10.1111/nep.12945.

PMID:
27718506
3.

High Ultrafiltration Rates Increase Troponin Levels in Stable Hemodialysis Patients.

Mavrakanas TA, Sniderman AD, Barré PE, Vasilevsky M, Alam A.

Am J Nephrol. 2016;43(3):173-8. doi: 10.1159/000445360. Epub 2016 Apr 12.

PMID:
27064739
4.

Elevated troponin I levels but not low grade chronic inflammation is associated with cardiac-specific mortality in stable hemodialysis patients.

Alam A, Palumbo A, Mucsi I, Barré PE, Sniderman AD.

BMC Nephrol. 2013 Nov 9;14:247. doi: 10.1186/1471-2369-14-247.

5.

A prospective evaluation of renal replacement therapy modality eligibility.

Mendelssohn DC, Mujais SK, Soroka SD, Brouillette J, Takano T, Barre PE, Mittal BV, Singh A, Firanek C, Story K, Finkelstein FO.

Nephrol Dial Transplant. 2009 Feb;24(2):555-61. doi: 10.1093/ndt/gfn484. Epub 2008 Aug 28.

PMID:
18755848
6.
7.

Predialysis psychoeducational intervention extends survival in CKD: a 20-year follow-up.

Devins GM, Mendelssohn DC, Barré PE, Taub K, Binik YM.

Am J Kidney Dis. 2005 Dec;46(6):1088-98.

PMID:
16310575
8.

Cobalamin dose regimen for maximum homocysteine reduction in end-stage renal disease.

Hoffer LJ, Saboohi F, Golden M, Barré PE.

Metabolism. 2005 Jun;54(6):835-40.

PMID:
15931623
9.

Predialysis psychoeducational intervention and coping styles influence time to dialysis in chronic kidney disease.

Devins GM, Mendelssohn DC, Barré PE, Binik YM.

Am J Kidney Dis. 2003 Oct;42(4):693-703.

PMID:
14520619
10.

Convergence of health ratings across nephrologists, nurses, and patients with end-stage renal disease.

Devins GM, Paul LC, Barré PE, Mandin H, Taub K, Binik YM.

J Clin Epidemiol. 2003 Apr;56(4):326-31.

PMID:
12767409
11.

Long-term knowledge retention following predialysis psychoeducational intervention.

Devins GM, Hollomby DJ, Barré PE, Mandin H, Taub K, Paul LC, Guttmann R, Binik YM.

Nephron. 2000 Oct;86(2):129-34.

PMID:
11014981
12.

Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy.

Foley RN, Parfrey PS, Morgan J, Barré PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA.

Kidney Int. 2000 Sep;58(3):1325-35.

13.

Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease.

Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE.

J Am Soc Nephrol. 2000 May;11(5):912-6.

14.

A tale of two homocysteines--and two hemodialysis units.

Hoffer LJ, Bank I, Hongsprabhas P, Shrier I, Saboohi F, Davidman M, Bercovitch DD, Barré PE.

Metabolism. 2000 Feb;49(2):215-9.

PMID:
10690947
15.
16.

Clinical practice guidelines for vascular access. Canadian Society pf Nephrology.

Ethier JH, Lindsay RM, Barre PE, Kappel JE, Carlisle EJ, Common A.

J Am Soc Nephrol. 1999 Jun;10 Suppl 13:S297-305. No abstract available.

PMID:
10425613
17.

Long-term evolution of cardiomyopathy in dialysis patients.

Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE.

Kidney Int. 1998 Nov;54(5):1720-5.

18.

Mode of dialysis therapy and mortality in end-stage renal disease.

Foley RN, Parfrey PS, Harnett JD, Kent GM, O'Dea R, Murray DC, Barre PE.

J Am Soc Nephrol. 1998 Feb;9(2):267-76.

19.

Cardiac disease in diabetic end-stage renal disease.

Foley RN, Culleton BF, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE.

Diabetologia. 1997 Nov;40(11):1307-12.

PMID:
9389423
20.

The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease.

Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE.

Am J Kidney Dis. 1996 Jul;28(1):53-61.

PMID:
8712222
21.

Outcome and risk factors for left ventricular disorders in chronic uraemia.

Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE.

Nephrol Dial Transplant. 1996 Jul;11(7):1277-85.

PMID:
8672023
22.

Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease.

Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE.

J Am Soc Nephrol. 1996 May;7(5):728-36.

23.

Outcome and risk factors of ischemic heart disease in chronic uremia.

Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE.

Kidney Int. 1996 May;49(5):1428-34.

24.

Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease.

Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE.

Kidney Int. 1996 May;49(5):1379-85.

25.

Hypocalcemia, morbidity, and mortality in end-stage renal disease.

Foley RN, Parfrey PS, Harnett JD, Kent GM, Hu L, O'Dea R, Murray DC, Barre PE.

Am J Nephrol. 1996;16(5):386-93.

PMID:
8886175
26.

Impact of renal transplantation on uremic cardiomyopathy.

Parfrey PS, Harnett JD, Foley RN, Kent GM, Murray DC, Barre PE, Guttmann RD.

Transplantation. 1995 Nov 15;60(9):908-14.

PMID:
7491692
27.

The prognostic importance of left ventricular geometry in uremic cardiomyopathy.

Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barré PE.

J Am Soc Nephrol. 1995 Jun;5(12):2024-31.

28.

Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors.

Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS.

Kidney Int. 1995 Mar;47(3):884-90.

29.

Clinical and echocardiographic disease in patients starting end-stage renal disease therapy.

Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE.

Kidney Int. 1995 Jan;47(1):186-92.

30.

Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients.

Harnett JD, Kent GM, Barre PE, Taylor R, Parfrey PS.

J Am Soc Nephrol. 1994 Jan;4(7):1486-90.

31.

Live and learn: patient education delays the need to initiate renal replacement therapy in end-stage renal disease.

Binik YM, Devins GM, Barre PE, Guttmann RD, Hollomby DJ, Mandin H, Paul LC, Hons RB, Burgess ED.

J Nerv Ment Dis. 1993 Jun;181(6):371-6.

PMID:
8501458
32.

More on the treatment of end-stage renal disease.

Prichard SS, Barre PE, Levy M.

N Engl J Med. 1991 Aug 29;325(9):661. No abstract available.

PMID:
1861703
33.

The natural history of myocardial disease in dialysis patients.

Parfrey PS, Harnett JD, Barre PE.

J Am Soc Nephrol. 1991 Jul;2(1):2-12. Review.

34.

The Kidney Disease Questionnaire: a test for measuring patient knowledge about end-stage renal disease.

Devins GM, Binik YM, Mandin H, Letourneau PK, Hollomby DJ, Barre PE, Prichard S.

J Clin Epidemiol. 1990;43(3):297-307.

PMID:
2313319
35.

Outcome of congestive heart failure, dilated cardiomyopathy, hypertrophic hyperkinetic disease, and ischemic heart disease in dialysis patients.

Parfrey PS, Griffiths SM, Harnett JD, Taylor R, King A, Hand J, Barre PE.

Am J Nephrol. 1990;10(3):213-21.

PMID:
2143353
36.

The clinical course of left ventricular hypertrophy in dialysis patients.

Parfrey PS, Harnett JD, Griffiths SM, Taylor R, Hand J, King A, Barre PE.

Nephron. 1990;55(2):114-20.

PMID:
2141918
37.

Impact of left ventricular hypertrophy on survival in end-stage renal disease.

Silberberg JS, Barre PE, Prichard SS, Sniderman AD.

Kidney Int. 1989 Aug;36(2):286-90.

38.

Congestive heart failure in dialysis patients.

Parfrey PS, Harnett JD, Griffiths SM, Gault MH, Barré PE.

Arch Intern Med. 1988 Jul;148(7):1519-25.

PMID:
3382298
39.

A randomized double blind trial of dialysate sodiums of 145 mEq/L, 150 mEq/L, and 155 mEq/L.

Barré PE, Brunelle G, Gascon-Barré M.

ASAIO Trans. 1988 Jul-Sep;34(3):338-41.

PMID:
3196530
40.

Sporadic aluminum osteomalacia: identification of patients at risk.

Turner MW, Ardila M, Hutchinson T, Prichard S, Barré PE, Beauvais J, Kaye M.

Am J Kidney Dis. 1988 Jan;11(1):51-6.

PMID:
3337100
41.

Does the maternal kidney contribute to the increased circulating 1,25-dihydroxyvitamin D concentrations during pregnancy?

Turner M, Barré PE, Benjamin A, Goltzman D, Gascon-Barré M.

Miner Electrolyte Metab. 1988;14(4):246-52.

PMID:
3211093
42.

Hydroxychloroquine treatment of hypercalcemia in a patient with sarcoidosis undergoing hemodialysis.

Barré PE, Gascon-Barré M, Meakins JL, Goltzman D.

Am J Med. 1987 Jun;82(6):1259-62.

PMID:
3605143
43.

Low-output left ventricular failure in end-stage renal disease.

Parfrey PS, Harnett JD, Griffiths S, Gault MH, Barre PE, Guttmann RD.

Am J Nephrol. 1987;7(3):184-91.

PMID:
3307413
44.

A prospective study on the impact of the renal biopsy in clinical management.

Turner MW, Hutchinson TA, Barré PE, Prichard S, Jothy S.

Clin Nephrol. 1986 Nov;26(5):217-21.

PMID:
3802585
45.

Routine clinical applications of hemodialysis-hemoperfusion in chronic renal failure: case reports.

Barré PE, Gonda A, Chang TM.

Int J Artif Organs. 1986 Sep;9(5):305-8.

PMID:
3023242
46.

Combined hemofiltration and desferrioxamine treatment for aluminum induced osteomalacia.

Barré PE, Prichard S.

Int J Artif Organs. 1986 May;9(3):167-72.

PMID:
3733242
47.

Osteoclast enlargement in endstage renal disease.

Kaye M, Zucker SW, Leclerc YG, Prichard S, Hodsman AB, Barré PE.

Kidney Int. 1985 Mar;27(3):574-81.

48.

The emotional impact of end-stage renal disease: importance of patients' perception of intrusiveness and control.

Devins GM, Binik YM, Hutchinson TA, Hollomby DJ, Barré PE, Guttmann RD.

Int J Psychiatry Med. 1983-1984;13(4):327-43.

PMID:
6671863
49.

Pain, control over treatment, and compliance in dialysis and transplant patients.

Binik YM, Baker AG, Kalogeropoulos D, Devins GM, Guttmann RD, Hollomby DJ, Barré PE, Hutchison T, Prud'Homme M, McMullen L.

Kidney Int. 1982 Jun;21(6):840-8.

50.

Helplessness and depression in end-stage renal disease.

Devins GM, Binik YM, Hollomby DJ, Barré PE, Guttmann RD.

J Abnorm Psychol. 1981 Dec;90(6):531-45. No abstract available.

PMID:
7033322

Supplemental Content

Loading ...
Support Center